Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research
The funding was awarded under the Foundationís Therapeutics Development Initiative. This program, first launched in 2006, supports and bolsters industry-focused efforts on Parkinsonís research.
The funded projects are listed below. Full information, including grant abstracts and researcher bios, is available on the Foundationís Web site ó www.michaeljfox.org.
Cerebrospinal Fluid (CSF) Biomarkers of Microtubule-mediated Axonal Transport for Monitoring of Disease Progression and Therapeutics Interventions in Parkinsonís Disease
Patrizia Fanara, PhD, KineMed, Inc.
Selective Inhibition of Cyclic Nucleotide Phosphodiesterase Type 7 (PDE7): A Novel and Efficacious Approach to Treating Parkinsonís Disease
Vincent Allen Florio, PhD, Omeros Corporation
Development of ER-beta Agonists for the Treatment of Parkinsonís Disease
Roger Olsson, PhD, and Krista McFarland, PhD, Acadia Pharmaceuticals, Inc.
Multiphosphatase Inhibitors as Therapeutics for Parkinsonís Disease
Arnon Rosenthal, PhD, and Franz F. Hefti, PhD, ShanaRX†